Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy
Important results from the OPTIMA study (“Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis”) were presented at ASCO this weekend by Dr. Robert C. Stein. This UCL-sponsored Phase III trial marks a significant milestone in moving towards more tailored, patient-centric oncological care.
The study demonstrated that many patients aged 40 and over with hormone-sensitive early breast cancer and a low Prosigna score (defined as ≤ 60) can safely avoid chemotherapy. By opting for hormone therapy alone, patients achieved excellent results without compromising their short-term outcomes.
Data from the trial showed that more than two-thirds of participants had a low Prosigna score, with remarkably similar outcomes across groups. Specifically, 94.8% of patients receiving chemotherapy plus hormone therapy were alive and free from recurrence at 5 years, compared with 93.6% of those treated with hormone therapy alone.
These findings strongly reinforce the clinical value of the Prosigna test and its ≤ 60 threshold to identify patients unlikely to benefit from chemotherapy. Sparing individuals from unnecessary toxicity significantly improves health trajectories, quality of life, and overall patient-reported outcomes.
Looking ahead, OPTIMA also highlights the urgent need for further research in premenopausal patients. To build a definitive, confident strategy for younger women, data from OPTIMA will be combined with global efforts including the OPTIMA premenopausal extension, Europe's OPTIMA-YOUNG trial, and the US-based OFSET trial.
Congratulations to the entire OPTIMA team on this monumental achievement. We are deeply grateful to continue this vital effort with you, alongside all the dedicated partners, investigators, and institutions associated with our international consortium. Let’s bring this innovation to all premenopausal patients.
